TOLREMO Therapeutics AG CHF 9 Series A Financing Round

Walder Wyss advises BiomedPartners AG as Lead Investor in connection with TOLREMO’s Series A Financing Round. TOLREMO was founded as an ETH spin-off on ground-breaking scientific discoveries in the field of drug resistance in cancer. The Financing Round was subscribed by BioMedPartners, Redalpine and Altos Venture as well as existing shareholders.

The Walder Wyss team comprises Alexander Gutmans (Partner, Corporate, Venture Capital) as well as Jessica Aeschbach Flórez (Associate, Corporate).